EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Impact of GLP-1 Receptor Agonist Therapy on Outcomes in Hidradenitis Suppurativa: A TriNetX Database Study

Sean Frisbie, Diwakar Phuyal, Emanuella Brito, Chinenye Ogbonnah, James Gaston, Risal Djohan, Eliana Duraes

SKIN The Journal of Cutaneous Medicine · 2026-11-10 · 10 (6) · 3491-3495

DOI: 10.25251/5swch621 ↗
AbstractBibliografische Angaben

Abstract

Background: Hidradenitis Suppurativa is a chronic inflammatory disorder strongly associated with obesity and metabolic dysfunction.1 Glucagon-like peptide-1 receptor agonists (GLP-1RA) demonstrate weight-loss and anti-inflammatory effects that may influence postoperative healing.1-3 We evaluated postoperative complications following hidradenitis excision among patients receiving GLP-1RA therapy compared with non-users. Methods: This retrospective cohort study analyzed patients within the TriNetX database, aggregating electronic medical records and claims data from 70 healthcare organizations representing over 101 million patients. Included patients underwent hidradenitis excision involving the axillary (CPT-11450, CPT-11451), perianal/perineal/umbilical (CPT-11470, CPT-11471), or inguinal regions (CPT-11462, CPT-11463). Cohorts were stratified by preoperative GLP-1RA use, including Semaglutide, Tirzepatide, Liraglutide, Dulaglutide, or Exenatide, prescribed up to one day prior to surgery. One-to-one propensity score matching was performed for age, sex, race, ethnicity, comorbidities, HS-related procedures, and immunosuppressive therapy. Outcomes assessed at 1 and 3 months postoperatively included infection, debridement, reoperation, wound dehiscence, sepsis, thromboembolic events, emergency department visits, and overall complications. Reoperation was defined as repeat hidradenitis excision occurring ≥1 day after index surgery. Results: After propensity score matching, 2,992 patients were included (1,496 per cohort), with balanced baseline characteristics (standardized mean differences

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →